AnaptysBio, Inc.
10421 Pacific Center Court
Suite 200
San Diego
California
92121
United States
Tel: 858-362-6295
Fax: 858-362-6296
Website: http://www.anaptysbio.com/
Email: info@anaptysbio.com
About AnaptysBio, Inc.
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps.
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Stock Exchange: NASDAQ
Stock Symbol: ANAB
67 articles with AnaptysBio, Inc.
-
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint
11/8/2019
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis.
-
AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates
11/8/2019
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30, 2019 and provided pipeline updates.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
Shares of AnaptysBio were climbing this morning after the company released positive interim data for its experimental peanut allergy treatment. The San Diego-based company said 13 patients or 46 percent of those in its ongoing Phase IIa trial saw increased tolerance to peanuts to 500 mg.
-
4 Biotechs Ready to Kill the Market in 2018
12/29/2017
A look at a few biotechs which should outperform the market in 2018. -
Top 5 Biotech Stocks to Buy for 2018
12/21/2017
A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why. -
The 2017 Biotech IPO Winners and Losers
12/21/2017
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs. -
Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.
-
AnaptysBio Reports Positive ANB019 Top-line Phase I Clinical Trial Results
11/7/2017
Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties that support advancement of ANB019 into patient Phase 2 studies.
-
AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates
11/7/2017
Cash, cash equivalents and investments totaled $116.7 million as of September 30, 2017, which includes net proceeds of $80.2 million from the company’s initial public offering completed in January 2017, compared to $51.2 million as of December 31, 2016.
-
AnaptysBio Announces Pricing Of Public Offering
10/13/2017
-
AnaptysBio Files Registration Statement For Proposed Public Offering
10/11/2017
-
AnaptysBio Reports Positive Topline Proof-Of-Concept Data From Phase IIa Clinical Trial Of ANB020 In Atopic Dermatitis
10/10/2017
-
AnaptysBio Announces Appointment Of J. Anthony Ware, M.D. To Board Of Directors
8/24/2017
-
AnaptysBio Announces Second Quarter 2017 Financial Results And Provides Pipeline Updates
8/11/2017
-
AnaptysBio Announces First Quarter 2017 Financial Results And Provides Pipeline Update
5/12/2017
-
AnaptysBio Release: SoCal Biotech Goes Public, Raises $75 Million
1/26/2017
-
AnaptysBio Release: Biotech Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer
1/11/2017
-
AnaptysBio Announces Clearance Of U.S. IND And U.K. CTA For ANB020
12/13/2016
-
AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
10/3/2016